NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma |
|
|
| Recruiting | 2 | 20 | US | Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA | AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas | Skin Kaposi Sarcoma | 03/24 | 04/24 | | |
